Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Eur J Hosp Pharm ; 28(6): 350-352, 2021 11.
Article in English | MEDLINE | ID: mdl-32920533

ABSTRACT

A 70-year-old man with a history of hypertension was evaluated in our dermatology department due to the appearance of a clinical picture compatible with bullous pemphigoid that was confirmed histologically. The lack of response to topical and systemic immunosuppressive treatment resulted in omalizumab being prescribed in a multidisciplinary committee based on the clinical and analytical findings and the patient's refusal to be treated with rituximab. The evaluation at 3 months showed the absence of blisters on the clinical examination. No associated adverse effects were observed. In the following 3 months the patient was administered medication at home in the absence of an anaphylactic reaction and with prior training by the nursing staff of the Hospital Pharmacy Service. After 6 months the medication was suspended with no relapses for 6 months since the last dose. Omalizumab, an anti-IgE monoclonal drug which has a good safety profile with minimum adverse side effects should be considered when there is a contraindication to the use of intravenous therapies (eg, immunoglobulins, rituximab) or prolonged immunosuppressive treatment (eg, methotrexate, azathioprine).


Subject(s)
Omalizumab , Pemphigoid, Bullous , Aged , Humans , Immunosuppressive Agents/therapeutic use , Male , Omalizumab/therapeutic use , Pemphigoid, Bullous/chemically induced , Pemphigoid, Bullous/drug therapy , Rituximab/adverse effects , Rituximab/therapeutic use
2.
Pharmacogenet Genomics ; 31(2): 40-47, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33044390

ABSTRACT

OBJECTIVES: Multiple sclerosis (MS) is a neurodegenerative chronic inflammatory. Mutations in the vitamin D receptor (VDR) gene can substantially affect serum vitamin D levels or alter its functionality, and can consequently increase susceptibility to developing MS. The objective of this study was to evaluate the association between polymorphisms in the VDR gene and risk of MS in a (Spanish) Caucasian population. PATIENTS AND METHODS: We conducted a retrospective case-control study comprising 209 patients with relapsing-remitting multiple sclerosis (RRMS) and 836 controls of Caucasian origin from southern Spain. The ApaI (rs7975232), BsmI (rs1544410), Cdx2 (rs11568820), FokI (rs2228570), and TaqI (rs731236) gene polymorphisms were determined by allelic discrimination real-time PCR using TaqMan probes. RESULTS: The recessive logical regression model, adjusted for age and sex, revealed that the TT genotype for VDR FokI (rs2228570) polymorphism was associated with higher risk of MS (P = 0.0150; OR = 1.82; 95% CI = 1.12-2.94; TT vs. CT + CC). No association between the other polymorphisms and development of MS was found in any of the models analyzed. The haplotype analysis, adjusted for age, smoking, and sex, did not find any statistically significant association between the haplotypes analyzed and risk of MS. CONCLUSIONS: The VDR FokI (rs2228570) polymorphism was significantly associated with developing MS. We found no influence of the ApaI (rs7975232), BsmI (rs1544410), Cdx2 (rs11568820), FokI (rs2228570), and TaqI (rs731236) gene polymorphisms on the risk of developing MS in our patients.


Subject(s)
Genetic Association Studies , Genetic Predisposition to Disease , Multiple Sclerosis/genetics , Polymorphism, Single Nucleotide/genetics , Receptors, Calcitriol/genetics , Adult , Alleles , Female , Genotype , Haplotypes/genetics , Humans , Male , Middle Aged , Multiple Sclerosis/epidemiology , Multiple Sclerosis/pathology , Risk Factors , Spain/epidemiology , White People/genetics
3.
J Oncol Pharm Pract ; 26(1): 252-255, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31382863

ABSTRACT

Immune checkpoint inhibitors have become a target for pharmacological research in lung cancer. Immune-related adverse events (irAEs) such as pneumonitis, colitis, hepatitis and endocrinopathies have been well characterized in immune checkpoint inhibitors, but coronary toxicities, like acute coronary syndrome, are poorly described. Herein, we report a possible acute coronary syndrome as immune-related adverse event in a lung cancer patient.


Subject(s)
Acute Coronary Syndrome/chemically induced , Antineoplastic Agents, Immunological/adverse effects , Colitis/chemically induced , Lung Neoplasms/drug therapy , Nivolumab/adverse effects , Aged , Humans , Male , Recurrence
5.
Sultan Qaboos Univ Med J ; 19(4): e369-e371, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31897322

ABSTRACT

We report a 50-year-old male patient who presented to the Dermatological Outpatient Clinic at the Hospital Universitario San Cecilio, Granada, Spain, in 2017 with symmetrical inguinal eruption and eruption on the dorsum of both feet four hours after the intake of amoxicillin. Physical examination showed confluent non-palpable purpuric macules covering the dorsum of both feet and medial malleolus, giving rise to dusky erythema in some areas. Only oral antihistamines were prescribed and cutaneous exanthema resolved within three weeks. Symmetric drug-related intertriginous and flexural exanthema (SDRIFE) is a sub-type of systemic allergic contact dermatitis, where previous sensitisation can only be demonstrated in up to 50% of patients by skin patch testing. Therefore, a provocation test was performed with amoxicillin without prior skin patch testing. As drug provocation produced the same reaction, the patient was diagnosed with SDRIFE. A parvovirus B19 infection was ruled out by negative serology. SDRIFE is challenging to distinguish from other skin rashes with similar features and distribution; it is important to be aware of these characteristics and their possible causes.


Subject(s)
Amoxicillin/adverse effects , Anti-Bacterial Agents/adverse effects , Exanthema/chemically induced , Foot Dermatoses/chemically induced , Histamine Antagonists/therapeutic use , Amoxicillin/administration & dosage , Anti-Bacterial Agents/administration & dosage , Drug Eruptions , Exanthema/drug therapy , Exanthema/pathology , Foot Dermatoses/drug therapy , Foot Dermatoses/pathology , Humans , Male , Middle Aged , Treatment Outcome
7.
Cancer Treat Rev ; 37(2): 105-10, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20655664

ABSTRACT

Taxanes offer clear benefits in adjuvant chemotherapy for early breast cancer. This review examines evidence to date on the clinical effectiveness and cost-effectiveness of their use in the adjuvant treatment of women with early breast cancer, based on three meta-analyses, one systematic review, five clinical practice guidelines and 16 randomized clinical trials. Against the background of a major increase in the use of docetaxel rather than paclitaxel in our setting over the past few years, implying a major increase in costs, we examined whether this higher use of docetaxel is supported by the available evidence. In this wide study, we found no evidence that regimens containing docetaxel yield greater benefits than those including paclitaxel. From an effectiveness standpoint, the change from paclitaxel to docetaxel in our setting is not justified.


Subject(s)
Breast Neoplasms/drug therapy , Taxoids/therapeutic use , Breast Neoplasms/mortality , Chemotherapy, Adjuvant , Cost-Benefit Analysis , Disease-Free Survival , Docetaxel , Female , Humans , Paclitaxel/therapeutic use , Practice Guidelines as Topic
8.
J Clin Med Res ; 2(6): 281-3, 2010 Dec 11.
Article in English | MEDLINE | ID: mdl-22043263

ABSTRACT

UNLABELLED: Testicular epidermoid cyst is extremely rare injury, which in recent studies has been regarded as a tumor. Some authors consider this lesion as a cystic monodermal teratoma, the histogenesis remains controversial. In this study we provide clinical and morphological characteristics of an epidermoid cyst in the left testicle in a 16 years old patient, where apparently a nodular lesion in the left testicle was detected. KEYWORDS: Cyst; Epidermoid; Intratesticular.

SELECTION OF CITATIONS
SEARCH DETAIL
...